Clinical trials: Neck Cancer
HNSCC
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with…
- Trial name
- PEMDA-HN (NCT05814666)
- Testing
- Danvatirsen, Pembrolizumab
- Where
- 32 sites in United States, South Korea and 1 more
- Volunteers
- 69 people
- Sponsor
- Flamingo Therapeutics NV
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different…
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06678724
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04106362
- Testing
- Cetuximab, Cisplatin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
This phase II, open-label, randomized study will evaluate the efficacy and safety of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or…
- Trial name
- NCT01577173
- Testing
- MEHD7945A, cetuximab
- Where
- 51 sites in United States, Australia and 9 more
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Ovarian Cancer, Endometrial Cancer
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer
- Trial name
- NCT00315861
- Testing
- pemetrexed, topotecan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
Oral Complications of Chemotherapy and Head and Neck Radiation
Prevalence of Oral Side Effects Associated With Chemo and Radiotherapy for Treating Head and Neck Cancer
A cross-sectional study will be conducted to report oral complications during chemo and radiotherapy treatment in case of patients diagnosed with head and neck cancer and the effect of theses oral side effects on patients'…
- Trial name
- NCT04845854
- Where
- Egypt
- Volunteers
- 294 people
- Sponsor
- Cairo University
Esophageal Squamous Cell Carcinoma
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable…
- Trial name
- AdvanTIG-203 (NCT04732494)
- Testing
- Tislelizumab, Ociperlimab
- Where
- 86 sites in China, France and 4 more
- Volunteers
- 125 people
- Sponsor
- BeiGene
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Trial name
- NCT05232851
- Testing
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Uterine Cervical Neoplasms
Institut Paoli Calmettes Cervical Cancer Database
Database of Institut Paoli-Calmettes patients diagnosed with cervical cancer
- Trial name
- NCT02869490
- Testing
- Data collection
- Where
- France
- Volunteers
- 6,000 people
- Sponsor
- Institut Paoli-Calmettes
Nasopharyngeal Neoplasms
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
First-diagnosed metastasis or recurrence/metastasis NPC Patients will be treated with anlotinib, penpulimab and capecitabine.
- Trial name
- ALTER-HN005 (NCT05807880)
- Testing
- The combination treatment of anlotinib, penpulimab and capecitabine.
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004094
- Testing
- carboplatin, fluorouracil, hydroxyurea
- Where
- 4 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancers
Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).
This is a prospective non-randomized clinical trial to evaluate the feasibility of 3 fraction versus a standard 4 fraction high dose rate brachytherapy regimen in patients with locally advanced cervical cancer.
- Trial name
- NCT07022470
- Testing
- 3-Fraction HDR Brachytherapy, 4-Fraction HDR Brachytherapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Esophageal Neoplasm, Chemoradiation
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
In this phase II study, the investigators aim to evaluated the efficacy and toxicity of definitive concurrent chemoradiotherapy (CCRT) with docetaxel plus cisplatin (DP regimen) versus 5-fluorouracil plus cisplatin (PF regimen)…
- Trial name
- NCT02969473
- Testing
- Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhu Yujia
Head and Neck Cancer
Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT00771641
- Testing
- conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy
- Volunteers
- 1,113 people
- Sponsor
- Radiation Therapy Oncology Group
Nasopharyngeal Carcinoma, PD-1
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of…
- Conditions
- Nasopharyngeal Carcinoma, PD-1, Surgery
- Trial name
- NCT04778956
- Testing
- Toripalimab, salvage surgery
- Where
- 7 sites in China
- Volunteers
- 218 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Solid Tumors
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this trial was to explore the clinical utility of two investigational agents in patients with advanced cancer. This was a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT03301896
- Testing
- LHC165, PDR001
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Carcinoma to the Uterine Cervix, Recurrent Carcinoma Cervix
Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix
Experience with substituting carboplatin for cisplatin is limited in advanced and recurrent cervix cancer and there has been no counterpart to GOG 158, which documented therapeutic equivalency of cisplatin/paclitaxel and…
- Conditions
- Metastatic Carcinoma to the Uterine Cervix, Recurrent Carcinoma Cervix, Cervix Carcinoma Recurrent
- Trial name
- NCT02492503
- Testing
- Paclitaxel and carboplatin
- Where
- India
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences
Ovarian Cancer, Endometrial Cancer
ASk Questions in GYnecologic Oncology (ASQ-GYO)
The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge…
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer
- Trial name
- ASQ-GYO (NCT06339827)
- Testing
- Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Ira Winer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.